

Mathieu Kerneis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5813460/publications.pdf>

Version: 2024-02-01

24
papers

535
citations

840585

11
h-index

677027

22
g-index

25
all docs

25
docs citations

25
times ranked

795
citing authors

#	ARTICLE	IF	CITATIONS
1	ST-segment elevation myocardial infarction. <i>Nature Reviews Disease Primers</i> , 2019, 5, 39.	18.1	179
2	Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. <i>European Heart Journal</i> , 2022, 43, 2783-2797.	1.0	74
3	Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 1-9.	1.0	36
4	Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. <i>American Journal of Medicine</i> , 2018, 131, 972.e1-972.e7.	0.6	29
5	Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 626-634.	1.1	25
6	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. <i>American Heart Journal</i> , 2019, 208, 81-90.	1.2	25
7	Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2389-2395.	1.8	22
8	D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy). <i>American Journal of Cardiology</i> , 2018, 122, 1459-1464.	0.7	21
9	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. <i>American Heart Journal</i> , 2018, 198, 84-90.	1.2	19
10	Anticoagulation in Acute Coronary Syndrome-State of the Art. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 508-513.	1.6	14
11	Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 1-8.	1.0	14
12	Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007124.	1.4	11
13	Silent Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2018, 71, 9-11.	1.2	10
14	Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 346-350.	1.0	10
15	Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. <i>American Heart Journal</i> , 2018, 203, 17-24.	1.2	10
16	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. <i>TH Open</i> , 2018, 02, e16-e24.	0.7	8
17	Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. <i>Circulation</i> , 2019, 139, 1234-1236.	1.6	7
18	Most Promising Therapies in Interventional Cardiology. <i>Current Cardiology Reports</i> , 2019, 21, 26.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 524-530.	1.6	5
20	Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 845-855.	0.6	5
21	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. <i>TH Open</i> , 2019, 03, e103-e108.	0.7	1
22	Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008160.	1.4	1
23	SECURE PCI: how important can a subgroup analysis be?. <i>Journal of Thoracic Disease</i> , 2018, 10, S2032-S2034.	0.6	0
24	Conundrum of Using Real-World Observational Data to Inform Real-World Conclusions About Safety and Efficacy. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1801-1803.	1.2	0